William Wells: Peer-Reviewed Publications
Peer-reviewed publications in global public health include the following (click title to download the pdf):
Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjo M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016 doi: 10.1016/S1473-3099(16)30190-6.
Trajman A, Bastos ML, Belo M, Calaca J, Gaspar J, Dos Santos AM, Dos Santos CM, Brito RT, Wells WA, Cobelens FG, Vassall A, Gomez GB. Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services. BMC Health Serv Res. 2016. 16(1):27. doi: 10.1186/s12913-016-1269-x.
Knight GM, Gomez GB, Dodd P, Dowdy D, Zwerling A, Wells WA, Cobelens F, Vassall A, White RW. The impact and cost-effectiveness of a four-month regimen for first-line treatment of active tuberculosis in South Africa. PLoS ONE. 2015. 10(12):e0145796. doi: 10.1371/journal.pone.0145796.
Wells WA, Uplekar M, Pai M. Achieving systemic and scalable private sector engagement in tuberculosis care and prevention in Asia. PLoS Med. 2015. 12(6): e1001842. doi:10.1371/journal.pmed.1001842.
Denkinger CM, Dolinger D, Schito M, Wells WA, Cobelens F, Pai M, Zignol M, Cirillo DM, Alland D, Casenghi M, Gallarda J, Boehme CC, Perkins MD. Target product profile of a molecular drug-susceptibility test for use in microscopy centers. J Infect Dis. 2015. 211(suppl 2):S29-S38.
Gospodarevskaya E, Tulloch O, Bunga C, Ferdous S, Jonas A, Islam S, Rahman M, Hussain MA, Haque MN, Egwaga S, Gardiner E, PrayGod G, Islam MA, Mann GH, Wells WA, Squire SB. Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens. Int J Tuberc Lung Dis. 2014. 18:810-7.
Wells WA, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis. 2013. 13:449-58.
Eang MT, Vun MC, Eam KK, Sovannarith S, Sopheap S, Bora N, Yadav R, Fujita M, Tomas B, Ghidinelli M, van Maaren P, Wells WA. The multi-step process of building TB/HIV collaboration in Cambodia. Health Res Policy Syst. 2012. 10:34.
Wells WA, Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME. Size and usage patterns of private TB drug markets in the high burden countries. PLoS ONE. 2011. 6:e18964. Findings from this study were picked up by the Financial Times (see full text), Nature Medicine, the Telegraph (Calcutta), the Times of India, Aidsmap, and Radio Australia.
Wells WA, Konduri N, Chen C, Lee D, Ignatius HR, Gardiner E, Schwalbe NR. Implications of the current tuberculosis treatment landscape for future regimen change. Int J Tuberc Lung Dis. 2011. 15:746-53.
Wells WA, Brooks A. Adoption of new health products in low and middle income settings: How product development partnerships can support country decision making. Health Res Policy Syst. 2011. 9:15.
Wells WA, Konduri N, Chen C, Lee D, Ignatius HR, Gardiner E, Schwalbe NR. Tuberculosis regimen change in high-burden countries. Int J Tuberc Lung Dis. 2010. 14:1538-47.
Brooks AD, Wells WA, McLean TD, Khanna R, Coghlan R, Mertenskoetter T, Privor-Dumm LA, Krattiger A, Mahoney RT. Ensuring that developing countries have access to new healthcare products: The role of product development partnerships. Innov Strat Today. 2010. 3:1-5.
Schwalbe NR, Wells WA, Geaneotes AP, Forcellina A, Lee MG, Dicola L, Ignatius HR, Walker CL, Raafat T, Patel N. Estimating the market for tuberculosis drugs in industrialized and developing nations. Int J Tuberc Lung Dis. 2008. 12:1173-81.
Home Page | Intnl Public Health | Writing | Education | Publications | Resume | Contact